3. Results
cancer
CANCER, MAY, RECRUITMENT
The study opened at 3 Canadian cancer centres in Ontario, Canada (London, Ottawa, and Thunder Bay) on 1 May 2019, 19 August 2019 and 27 February 2020, respectively, and closed on 13 March 2021 at all sites. Between May 2019 and March 2021, 52 patients were approached to enter this study. Three patients declined the study. The most common reason was patient treatment preference. All remaining 49 patients were eligible and met all inclusion criteria.Of the 49 eligible patients, 25 (51%) were randomized to P-H and 24 (49%) to TC-H. The consort flow diagram depicting patient flow is shown in Of 49 patients who agreed to participate in the trial and were randomized, 47 (95%) received their treatment as per protocol. As the study ran for 23, 20, and 14 months at the London, Ottawa, and Thunder Bay sites, respectively, the overall duration of the study was 23 months. Therefore, the recruitment rate was 2.13 patients per month.Treatment information is provided in 